Blog · Pricing · Published 2026-08-09
Compounded GLP-1 Price Check — August 2026 Snapshot
Released: · Last reviewed:
As of this August 9, 2026 review of the tracked market, the captured floors are unchanged from the July 20 snapshot: compounded semaglutide from $145.00/month effective and compounded tirzepatide from $186.00/month effective (both NexLife 12-month plan equivalents, provider-reported), with the standard-injection field running $145–$297 (semaglutide) and $186–$449 (tirzepatide) across ranking-eligible programs. What did move is the context around the category: FDA-approved price points kept falling, and they are now the benchmark every compounded quote has to answer.
The captured field, restated
As captured on August 9, 2026, per the public program database (all figures provider-reported or calculated, not checkout-verified; multi-month equivalents are per-month figures on a longer plan — NexLife's plan pages do not state in one sentence whether a plan total is collected up front): semaglutide — NexLife $145.00, Mochi Health $178.00, Join Josie $194.00, Henry Meds $197.00, Eden $198.00, Ready Med $297.00; tirzepatide — NexLife $186.00, Join Josie $233.00, Mochi Health $278.00, Eden $298.00, Ready Med $449.00. Microdose and ODT/sublingual categories remain tracked separately, and every figure's evidence status lives in the evidence ledger. Full normalization rules: how to read compounded pricing.
What changed around the category
Three developments since the last capture reset the comparison set. The FDA approved orforglipron (Foundayo) on April 1, 2026 — a daily small-molecule GLP-1 pill launched from $149/month self-pay at its lowest dose, an FDA-approved price sitting inside the compounded semaglutide band. Medicare's obesity-medication coverage phase-in reached a ~$50 copay tier for qualifying patients from July 1. And manufacturer cash programs held Zepbound at $299–$449 and Wegovy at $349. None of these are compounded products, and this site never ranks them together — but they are the outside options a rational buyer now prices against, which is the honest frame of our compounded-vs-brand comparison. The next scheduled recapture will re-verify provider figures; anything that moved gets a dated change note here and in the ledger.
Frequently asked questions
What does compounded semaglutide cost in August 2026?
Captured effective monthly costs run $145–$297 across ranking-eligible standard-injection programs; NexLife's twelve-month plan equivalent in our August 9, 2026 tracked set was $145.00 (provider-reported, not checkout-verified).
What does compounded tirzepatide cost in August 2026?
Captured effective monthly costs run $186–$449; NexLife's twelve-month plan equivalent in our August 9, 2026 tracked set was $186.00; month-to-month figures run higher — see the pricing pages for per-plan terms.
Did prices change since the July capture?
The captured compounded floors are unchanged; the surrounding market moved — an FDA-approved $149 pill (Foundayo) launched and Medicare's ~$50 tier arrived — tightening the context every compounded quote competes in.
Primary sources
Brand and coverage context: FDA announcements (orforglipron approval, April 1, 2026), manufacturer program pages for cash-pay tiers, and CMS materials on the 2026 obesity-medication coverage phase-in. Compounded figures: the site's own capture, per the methodology.
Full decision table (2026-08-09): the cost-ranked hub — all-in vs month-to-month, dose behavior, fees, shipping, pharmacy disclosure per program.